Quick Answer
Oncotelic Therapeutics, Inc. reported Net Income Loss of -$4.52 million for the year ending 2024.
- Oncotelic Therapeutics, Inc. showed an increase of +42.8% in Net Income Loss from 2023 to 2024.
- This data is from Oncotelic Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2009 to 2024 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: -$1.88 million | Q2 2013: -$1.65 million | Q3 2013: -$2.65 million | Q1 2014: -$2.63 million | Q2 2014: -$3.93 million | Q3 2014: -$3.45 million | Q1 2015: -$2.77 million | Q2 2015: -$3.32 million | Q3 2015: -$3.59 million | Q1 2016: -$3.33 million | Q2 2016: -$3.64 million | Q3 2016: -$3.24 million | Q1 2017: -$3.96 million | Q2 2017: -$3.88 million | Q3 2017: -$3.54 million | Q1 2018: -$190.8 thousand | Q2 2018: -$153.3 thousand | Q3 2018: -$214.0 thousand | Q1 2019: -$976.1 thousand | Q2 2019: -$1.19 million | Q3 2019: -$991.1 thousand | Q1 2020: -$4.66 million | Q2 2020: $582.1 thousand | Q3 2020: -$1.99 million | Q1 2021: -$2.80 million | Q2 2021: -$3.23 million | Q3 2021: -$1.56 million | Q1 2022: -$4.85 million | Q2 2022: $16.01 million | Q3 2022: -$777.9 thousand | Q1 2023: -$525.4 thousand | Q2 2023: -$6.76 million | Q3 2023: $115.3 thousand | Q1 2024: -$408.7 thousand | Q2 2024: -$209.8 thousand | Q3 2024: -$3.30 million | Q1 2025: -$298.7 thousand | Q2 2025: $277.9 thousand | Q3 2025: -$1.05 million.
- Over the full 16 years of available data (2009 to 2024), Oncotelic Therapeutics, Inc.'s Net Income Loss has grown by 81.7%.
- Historical annual values: Fiscal year 2024: -$4.52 million | Fiscal year 2023: -$7.90 million | Fiscal year 2022: $5.09 million | Fiscal year 2021: -$9.39 million | Fiscal year 2020: -$9.50 million | Fiscal year 2019: -$6.64 million | Fiscal year 2018: -$712.7 thousand | Fiscal year 2017: -$13.81 million | Fiscal year 2016: -$13.65 million | Fiscal year 2015: -$13.65 million | Fiscal year 2014: -$12.65 million | Fiscal year 2013: -$8.28 million | Fiscal year 2012: -$8.08 million | Fiscal year 2011: -$9.65 million | Fiscal year 2010: -$23.77 million | Fiscal year 2009: -$24.73 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: